• NMN and SIRT3 in Diabetic Myocardial Fibrosis

  2026-09-25

  A 2026 mouse study reports that nicotinamide mononucleotide attenuated diabetes-associated myocardial fibrosis alongside increased SIRT3, reduced GSK3β acetylation, and lower Smad3 phosphorylation. The proposed SIRT3–GSK3β–Smad3 pathway offers a testable framework for preclinical research, but the findings do not establish a definitive molecular mechanism or a treatment effect in people.

• Amplex Red Workflows for Iron-Linked Redox Studies

  2026-09-25

  Pair sensitive hydrogen peroxide measurement with mechanistic tests of iron-dependent inflammation—without mistaking one readout for another. This practical guide covers plate-based Amplex Red workflows, controls, and interpretation for oxidative stress and allergic airway research.

• (S)-(+)-Methoprene: Separating JH Supply from Signal

  2026-09-24

  See how (S)-(+)-Methoprene, a juvenile hormone analog, can help distinguish changes in hormone production from changes in hormone response. A recent locust study reveals why this separation matters when interpreting vitellogenesis, miRNA regulation, and developmental assays.

• SB-505124 Hydrochloride: Practical Research Workflows

  2026-09-24

  Use SB-505124 hydrochloride to test ALK4/5/7-dependent TGF-β/activin signaling in fibrosis-focused experiments, with practical readouts from Smad phosphorylation to CTGF and α-SMA. The workflows also show how to connect pathway perturbation to cell-mechanics assays without implying that this inhibitor has been shown to alter the MRTFA–KCNMB1 axis.

• CHK1 Inhibition in Breast Cancer: ER/PR Status Matters

  2026-09-23

  This study shows that CHK1 inhibition has different effects across breast cancer subtypes: it sensitizes ER−/PR−/HER2− cells to adriamycin, but does not improve adriamycin toxicity in ER+/PR+/HER2− cells. The work links these differences to distinct cell-cycle and apoptosis pathways, supporting receptor status as a factor in designing preclinical CHK1-targeted strategies.

• HOXC9, AKT/mTOR, and ESCC Apoptosis

  2026-09-23

  A 2026 study identifies HOXC9 as a potential upstream regulator of esophageal squamous cell carcinoma progression, linking its expression to enhanced proliferation and reduced mitochondria-dependent apoptosis through AKT/mTOR signaling. The work combines patient-tissue analysis, genetic perturbation, transcriptomics, pathway inhibition, and xenograft experiments, while also highlighting the need for validation across clinical and molecular subtypes.

• I-BET-762: BET Inhibitor Workflow for Ferroptosis

  2026-09-22

  I-BET-762 provides a practical way to connect BET-dependent transcription with ROS accumulation, FSP1 control, and ferroptosis sensitivity. This workflow translates published combination data into reproducible assay design for cancer biology research, while preserving a separate path for inflammation and LPS-responsive gene studies.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-09-22

  Tamoxifen combines temporal control of conditional gene deletion with broad utility in breast cancer research and pathway-focused cell assays. This guide connects practical CreER workflows to the PINK1–mitochondrial iron findings while emphasizing formulation, controls, and interpretation limits.

• BCECF for Extracellular pH Assays

  2026-09-21

  BCECF converts extracellular acid–base changes into a quantitative dual-excitation ratio for ion transport, metabolism, and efferocytosis workflows. Its cell-impermeant design helps distinguish extracellular microenvironment changes from intracellular signaling in macrophage and neuropathic pain research.

• BMP4-GPX4 Protects RGCs in NMDA Glaucoma

  2026-09-21

  The reference study identifies the BMP4–GPX4 axis as a potential link between retinal ganglion cell protection, ferroptosis control, and retinal stem cell differentiation in an NMDA-induced mouse glaucoma model. Its integrated use of retinal markers, redox and iron measurements, transcript analysis, and protein assays provides a framework for evaluating how oxidative injury may limit cell-based retinal repair.

• WQ-C-401 Blocks PDGFR Signaling in Experimental PAH

  2026-09-20

  The reference study identifies WQ-C-401 as a selective PDGFR inhibitor that reduced pulmonary vascular remodeling, right ventricular hypertrophy, and hemodynamic abnormalities in monocrotaline-induced pulmonary arterial hypertension. Its combination of kinome profiling, cell-based signaling assays, and in vivo pathology provides a useful framework for evaluating PDGFR-directed interventions beyond oncology.

• Prochlorperazine Beyond Antiemesis: A Translational Map

  2026-09-19

  Prochlorperazine offers translational researchers a useful study model: a dopamine D2 receptor antagonist with antiemetic utility, broad receptor pharmacology, and emerging relevance to melanoma and antiviral research. This article connects mechanism, assay design, clinical safety, and evidence boundaries.

• ARCA Cy3 EGFP mRNA (5-moUTP) Workflow

  2026-09-18

  Use ARCA Cy3 EGFP mRNA (5-moUTP) to separate cellular uptake from productive translation in mammalian cell assays. Its covalent Cy3 label, EGFP reporter, ARCA cap, and 5-methoxyuridine modification support direct imaging, formulation screening, and reproducible delivery troubleshooting.

• Palbociclib (PD0332991) Cancer Research Workflows

  2026-09-18

  Build reproducible Palbociclib assays around Rb phosphorylation, DNA-content profiling, and apoptosis timing rather than relying on viability alone. The workflow also shows how to use CD109-driven colorectal cancer biology to formulate testable resistance hypotheses without confusing reference-study findings with established Palbociclib effects.

• TMEM16F Lipid Scrambling in Ferroptosis

  2026-09-17

  Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptosis that protects the plasma membrane from lipid peroxide–driven collapse. The study links this membrane repair-like response to tumor progression and shows that inhibiting TMEM16F can improve tumor immune rejection when combined with PD-1 blockade.

8500 records 1/567 page Next 12345 下5页 Last page